7月12日，在2026年(第43届)全国医药工业信息年会上，中国医药工业信息中心正式发布“2025年度中国医药工业主营业务收入前100位企业”榜单(行业通称“医药工业百强”)。康臣药业首度入围该榜单，并凭借稳健的财务表现与成长动能，获评“中国医药工业投资价值潜力企业”。 作为衡量中国医药工业发展水平的重要标尺，医药工业百强榜单严格依托工业和信息化部《中国医药工业统计年报》进行客观排序，颇具行业权威性与公信力。同期发布的“投资价值潜力企业”评选，围绕企业在研发创新、市场表现、盈利能力及资本市场回报等多维度进行综合研判。此次康臣药业入围百强并获评投资价值潜力企业，全面彰显了其综合实力与长期发展前景。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.